News for Aadi Biosciences, Inc. (AADI)

An announcement from Aadi Bioscience ( (AADI) ) is now available. Aadi Bioscience has entered into a Stock Purchase Agreement with KAKEN Pharmaceutical, selling its subsidiary, including the FYARRO business, for $100 million, which will fund operations into late 2028. Additionally, Aadi has secured an exclusive license for three novel ADC assets from WuXi Biologics and announced a $100 million PIPE financing to support the development of these assets, indicating a strategic shift towards leverag

DelveInsight analysts project a favorable treatment-resistant hypertension market expansion, primarily driven by a rise in prevalence and the expected...

A baker's dozen stocks are trading near their 52-week lows but could be due for a rebound soon, said the Stock Trader's Almanac's Jeffrey Hirsch.

Several approved therapies such as EYBELIS, Durysta, Alphagan-P, Rhopressa, etc. will drive the current therapeutic landscape of ocular hypertension in the...

Aadi Bioscience, Inc. (NASDAQ:NASDAQ:AADI) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ETCompany ParticipantsMarcy Graham - SVP of IR and Corporate CommunicationsScott...

/PRNewswire/ -- DelveInsight's Hypertension Market Insights report includes a comprehensive understanding of current treatment practices, hypertension emerging...

Aadi Biosciences is focused on developing and commercializing precision therapies for genetically defined cancers. Find out my rating for AADI stock here.

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...